Search - tctmd.com

Displaying 81 - 100 of 176

Sort: Relevancy | Date

News Daily News

Ezetimibe With Statin Therapy: Biggest Bang in Higher-Risk ACS Patients

Michael O'Riordan

August 22, 2019

News Daily News

TCTMD’s Top 10 Most Popular Stories for July 2019

Shelley Wood

July 31, 2019

News Conference News EAS 2019

Should Lp(a) Be Measured and Treated? Two Experts Hash Out Its Current Role

Michael O'Riordan

June 07, 2019

News Conference News EAS 2019

Absence of FH Diagnosis Linked to Increased Risk of Premature Mortality

Michael O'Riordan

June 05, 2019

News Conference News EAS 2019

Inclisiran Safe and Effective in Patients With Impaired Renal Function: ORION

Michael O'Riordan

June 04, 2019

News Conference News EAS 2019

CHD Mortality Significantly Elevated in Patients With Severe FH

Michael O'Riordan

May 29, 2019

News Conference News EAS 2019

Clear CVD Risk Reduction With PCSK9 Inhibitors, but No Mortality Effect: Meta-analysis

Michael O'Riordan

May 28, 2019

News Daily News

PCSK9 Inhibitor Alirocumab Receives Expanded Indication for CV Event Reduction

Michael O'Riordan

April 29, 2019

News Conference News ACC 2019

Modest LDL Cholesterol Reduction With Bempedoic Acid in Among High-Risk Patients: CLEAR Wisdom

Michael O'Riordan

March 20, 2019

News Conference News AHA 2018

Alirocumab Should Be Priced at $6,300 Annually: ODYSSEY Cost-Effectiveness Study

Michael O'Riordan

November 15, 2018

Presentation Controversies and Advances 2018

Updateon PCS K-9 Inhibition

Presenter: P.K. Shah

November 15, 2018

News Conference News AHA 2018

AHA 2018: New Cholesterol Guidelines, Fish Oil, Diabetes Meds, and Inflammation Blow Into the Windy City

Shelley Wood

November 05, 2018

News Features

The Price of Knowledge: Industry-Sponsored Studies in the Era of Evidence-Based Medicine

Shelley Wood

October 22, 2018

News Daily News

Starting Low and Going Lower: Some Benefit to Very Low LDL Levels

Michael O'Riordan

August 02, 2018

News Daily News

Serial CTA Shines a Light on Statin Effects in Subclinical CAD

Yael L. Maxwell

June 15, 2018

News Daily News

Alirocumab Price Slashed in Deal With Express Scripts

Michael O'Riordan

May 03, 2018

News Daily News

Silent MI Often Precedes Acute MI, Portends Worse Patient Outcomes

Shelley Wood

April 18, 2018

News Conference News ACC 2018

High CRP Linked to Bigger Absolute Drops in CV Events for Patients Taking Evolocumab

Michael O'Riordan

March 20, 2018

News Conference News ACC 2018

ACC 2018, Day One: Live From Orlando! The ODYSSEY Begins

Shelley Wood

March 10, 2018

News Conference News ACC 2018

ACC 2018: More PCSK9 Outcomes, Antiplatelet Insights, and LifeVest Data at Last

Shelley Wood

March 05, 2018

Advertisement

Ezetimibe With Statin Therapy: Biggest Bang in Higher-Risk ACS Patients

TCTMD’s Top 10 Most Popular Stories for July 2019

Should Lp(a) Be Measured and Treated? Two Experts Hash Out Its Current Role

Absence of FH Diagnosis Linked to Increased Risk of Premature Mortality

Inclisiran Safe and Effective in Patients With Impaired Renal Function: ORION

CHD Mortality Significantly Elevated in Patients With Severe FH

Clear CVD Risk Reduction With PCSK9 Inhibitors, but No Mortality Effect: Meta-analysis

PCSK9 Inhibitor Alirocumab Receives Expanded Indication for CV Event Reduction

Modest LDL Cholesterol Reduction With Bempedoic Acid in Among High-Risk Patients: CLEAR Wisdom

Alirocumab Should Be Priced at $6,300 Annually: ODYSSEY Cost-Effectiveness Study

Updateon PCS K-9 Inhibition

AHA 2018: New Cholesterol Guidelines, Fish Oil, Diabetes Meds, and Inflammation Blow Into the Windy City

The Price of Knowledge: Industry-Sponsored Studies in the Era of Evidence-Based Medicine

Starting Low and Going Lower: Some Benefit to Very Low LDL Levels

Serial CTA Shines a Light on Statin Effects in Subclinical CAD

Alirocumab Price Slashed in Deal With Express Scripts

Silent MI Often Precedes Acute MI, Portends Worse Patient Outcomes

High CRP Linked to Bigger Absolute Drops in CV Events for Patients Taking Evolocumab

ACC 2018, Day One: Live From Orlando! The ODYSSEY Begins

ACC 2018: More PCSK9 Outcomes, Antiplatelet Insights, and LifeVest Data at Last

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content